Jul. 28 at 4:26 AM
$TNFA
TNFA
β Set up like past low-float biotech runners π
β
Float: ~13M β ultra tight like
$SBFM,
$INM,
$IXHL before their runs
β
Institutional confidence: Morgan Stanley increased position 61% in Q1 2025 (holds 3.7%)
β
Imminent Phase 2b data β Isomyosamine trial started Feb, 150+ days passed
β
Warrant wall at
$0.364 β could be incentive to push above and raise capital
β
Oversold bounce + reclaim of 50DMA + falling wedge breakout
β
High short interest + retail starting to notice
π§ Similar past plays:
β’
$SBFM β Ran from
$0.22 to
$1.60 on cancer data
β’
$INM β <
$0.20 to
$0.95 after clean Phase 2 and short squeeze
β’
$IXHL β Quiet under
$0.30, exploded past
$1+ on trial news
π― TNFA Price Targets:
β’ Base case:
$0.50β
$0.80
β’ Squeeze/FOMO:
$1+ like
$IXHL
This is one to keep eyes on. Microcap biotech, huge upside, real catalyst window NOW.
$TNFA
